And so we have our uh trade agreement with the European Union and it's a fair deal for both going to produce a lot of jobs and a lot of income and we have other many many other ones coming but you see the uh the level of enthusiasm is very good but the relationship that we have is fantastic. So I just want to congratulate you but Donald thank you very much. this now implements on car tariffs and aerospace our really important agreement and so this is a very good day for both of our countries a real sign so ...

Core Viewpoint - FibroBiologics, Inc. has successfully closed the third $5 million tranche of a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing the company to raise up to $25 million over two years for its therapeutic development efforts [1][2]. Financing Details - The SEPA allows FibroBiologics to sell up to $25 million in common stock to Yorkville over two years, with the first three tranches totaling $15 million being advanced in equal parts of $5 million each [2]. - The third tranche of $5 million was funded after the effectiveness of a registration statement and shareholder approval, complying with Nasdaq rules [2]. Use of Proceeds - The net proceeds from this financing are intended for general corporate purposes, including funding research and development programs and supporting an upcoming Phase 1/2 clinical trial for diabetic foot ulcers expected to start in the second half of 2025 [3]. Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials [7][8]. - The company holds over 275 patents issued and pending, covering various clinical pathways such as wound healing, multiple sclerosis, and cancer [8].

Core Insights - Equinor ASA has released its Energy Perspectives 2025 report, outlining four divergent scenarios for the global economy, energy markets, and greenhouse gas emissions amid rising geopolitical tensions and a delayed energy transition [1][9] Group 1: Emissions and Climate Action - Equinor's chief economist highlighted that the current geopolitical landscape and trade conflicts hinder global cooperation necessary for a Paris-aligned energy transition, with short-term political priorities overshadowing climate ambitions [2] - The report indicates that rising global greenhouse gas emissions in 2024 suggest a deviation from the 1.5°C climate target set by the Paris Agreement, with fragmentation in the global response to climate change posing significant risks [3] Group 2: Future Scenarios - The Energy Perspectives 2025 report presents four scenarios: Walls, Silos, Plazas, and Bridges, reflecting varying levels of cooperation, technological advancement, and policy direction, aimed at facilitating strategic thinking in an uncertain environment [4][9] - The "Walls" and "Silos" scenarios depict a fragmented world with slow progress on climate goals, while "Plazas" suggests moderate collaboration that still fails to meet the 1.5°C target; only the "Bridges" scenario aligns with the Paris Agreement but requires rapid global cooperation [5] Group 3: Long-Term Vision - Despite the challenges, the Bridges scenario indicates a potential pathway to a sustainable future aligned with the Paris Agreement, emphasizing the need for swift global cooperation to avoid a slower and more costly energy transition [6][7]

I think the biggest thing is is just get making sure that we're headed in the right direction. I think the WNBA has seen the visibility grow. I think the WNBA understands the impact of, you know, continuing to, I think, have those teams that are added to the mix, but for me, most importantly, yes, salary, but the second thing is roster spots.The roster spots have to increase. And that's been something that I've echoed over and over and over again to Neca Gumake is you've got to give these women a chance tha ...

Back to the big news this morning. So President Trump has posted that the framework trade agreement with China is a done deal and that will include upfront shipments of rare earths. But exact details of the pact remain fairly sketchy.Now, the President also says he will be sending letters to other trading partners in the next couple of weeks setting unilateral tariff rates. So we're dealing with Japan, we're dealing with South Korea, we're dealing with a lot of them. We're dealing with about 15 countries.Bu ...

Well, President Trump saying today that China will supply rare earth minerals upfront to the US. This coming as part of a larger trade agreement between the two countries. But our next guest says this is more of a ceasefire than an agreement that moves the ball forward. For more, we're bringing in now Bill Reich, senior adviser at the Center for Strategic and International Studies. Bill, it is good to see you. So, President Trump uh did make news this morning. Bill, he goes on social media. He says, "Listen ...

Chinese state media said earlier Wednesday Beijing had reached a “framework” for an agreement with the U.S. during talks in London. (Photo: Thomas Peter/Pool via Getty Images) https://t.co/E6qsHQmv89 https://t.co/HSmvykaLhw ...

President Donald Trump on Wednesday said a trade agreement was reached between the U.S. and China. https://t.co/fuo0IkQ79T https://t.co/fuo0IkQ79T ...

LIVE FROM WASHINGTON, D.C. JOE: TUESDAY EDITION, AS HOUSE REPUBLICANS LOOK ACROSS THE DIVIDE TO THE UPPER CHAMBER DEFINED PRESIDENT TRUMP'S BIG BEAUTIFUL BILL. I'M JOE MATHIEU ALONGSIDE KAILEY LEINZ IN WASHINGTON. IMPORTANT DAY IN THE NATION'S CAPITAL. WE ARE ABOUT TO LEARN A LOT ABOUT WHAT STAYS AND WHAT MIGHT COME OUT OF THE BILL WITH ACTION ON BOTH SIDES OF THE CAPITAL. KAILEY: SOME OF THAT BEING DRIVEN BY SENATORS WHO WANT CHANGE IN SOME DRIVEN BY PROCEDURE AND THE SENATE PARLIAMENTARIAN WHO IS GOING TO ...

Core Viewpoint - MacroGenics has entered into a royalty purchase agreement with Sagard, receiving a $70 million upfront payment for a capped royalty interest on future global net sales of its PD-1 inhibitor, ZYNYZ [1][2]. Group 1: Royalty Purchase Agreement - The agreement allows MacroGenics to receive an upfront payment of $70 million for its royalty rights on global net sales of ZYNYZ [2]. - After Sagard receives a total of $140 million in royalty payments (2.0x), MacroGenics will regain the right to collect all future royalties on global net sales [2]. Group 2: Financial Position - As of March 31, 2025, MacroGenics had $154.1 million in cash, cash equivalents, and marketable securities, which, along with the $70 million upfront payment and anticipated future payments, is expected to support its cash runway through the first half of 2027 [3]. Group 3: Product Information - ZYNYZ (retifanlimab-dlwr) is a humanized monoclonal antibody targeting PD-1, indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) [4]. - ZYNYZ is also indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S., approved under accelerated approval based on tumor response rate [5]. Group 4: Company Overview - MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for cancer treatment [6]. - The company generates its pipeline from proprietary next-generation antibody-based technology platforms and has entered into several strategic collaborations with global pharmaceutical and biotechnology companies [6]. Group 5: About Sagard - Sagard is a multi-strategy alternative asset management firm with over $25 billion under management, investing in various sectors including venture capital and private equity [7].